Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Dec;33(12):1578-1587.e5.
doi: 10.1016/j.jvir.2022.08.027. Epub 2022 Sep 6.

Accuracy and Safety of Scout Dose Resin Yttrium-90 Microspheres for Radioembolization Therapy Treatment Planning: A Prospective Single-Arm Clinical Trial

Nima Kokabi  1 , Linzi A Webster  2 , Mohammad Elsayed  2 , Jeffrey M Switchenko  3 , Bernard Chen  2 , David Brandon  4 , James Galt  4 , Ila Sethi  4 , Mircea Cristescu  5 , S Cheenu Kappadath  6 , David M Schuster  4
Affiliations
Clinical Trial

Accuracy and Safety of Scout Dose Resin Yttrium-90 Microspheres for Radioembolization Therapy Treatment Planning: A Prospective Single-Arm Clinical Trial

Nima Kokabi et al. J Vasc Interv Radiol. 2022 Dec.

Abstract

Purpose: To compare the accuracy and safety of 0.56 GBq resin yttrium-90 (90Y) (scout90Y) microspheres with those of technetium-99m macroaggregated albumin (MAA) in predicting the therapeutic 90Y (Rx90Y) dose for patients with hepatocellular carcinoma (HCC).

Materials and methods: This prospective single-arm clinical trial (Clinicaltrials.gov: NCT04172714) recruited patients with HCC. Patients underwent same-day mapping with MAA and scout90Y. Rx90Y activity was administered 3 days after mapping. Using paired t test and Pearson correlation, the tumor-to-normal ratio (TNR), lung shunt fraction (LSF), predicted mean tumor dose (TD), and nontumoral liver dose (NTLD) by MAA and scout90Y were compared with those by Rx90Y. Bland-Altman plots compared the level of agreement between the TNR and LSF of scout90Y and MAA with that of Rx90Y. The safety of scout90Y was evaluated by examining the discrepancy in extrahepatic activity between MAA and scout90Y.

Results: Thirty patients were treated using 19 segmental and 14 nonsegmental (ie, 2 contiguous segments or nonsegmental) therapies. MAA had weak LSF, moderate TNR, and moderate TD linear correlation with Rx90Y. Scout90Y had a moderate LSF, strong TNR, strong TD, and very strong NTLD in correlation with those of Rx90Y. Furthermore, the TNR and LSF of scout90Y had a stronger agreement with those of Rx90Y than with those of MAA. In the nonsegmental subgroup, MAA had no significant correlation with the TD and NTLD of Rx90Y, whereas scout90Y had a very strong correlation with both of these factors. In the segmental subgroup, both MAA and scout90Y had a strong linear correlation with the TD and NTLD of Rx90Y.

Conclusions: Compared with MAA, scout90Y is a more accurate surrogate for Rx90Y biodistribution for nonsegmental therapies.

PubMed Disclaimer

Conflict of interest statement

N.K. reports grant from Sirtex Medical Ltd, educational grant from Boston Medical, and consulting fees from Sirtex Medical Ltd. None of the other authors have identified a conflict of interest.

Figures

Figure 1.
Figure 1.
Study flowchart for each recruited patient. 90Y = yttrium-90; CBCT = cone-beam computed tomography; CT = computed tomography; f/u = follow-up; HCC = hepatocellular carcinoma; MAA = macroaggregated albumin; MR = magnetic resonance; PET = positron emission tomography; SIRT = selective internal radiation therapy; SPECT = single-photon emission computed tomography; Tc99 = technetium-99m; w/ = with.
Figure 2.
Figure 2.
Correlation of tumor-to-normal liver ratio (TNR) by yttrium-90 (90Y) mapping and 90Y treatment type: (a) macroaggregated albumin (MAA) versus therapeutic 90Y (Rx90Y) entire cohort, (b) MAA versus Rx90Y nonsegmental treatment, (c) MAA versus Rx90Y segmental treatment, (d) Scout90Y versus Rx90Y entire cohort, (e) Scout90Y versus Rx90Y nonsegmental treatment, and (f) Scout90Y versus Rx90Y segmental treatment.
Figure 3.
Figure 3.
The correlation of mean tumor dose by yttrium-90 (90Y) mapping and 90Y treatment type: (a) macroaggregated albumin (MAA) versus therapeutic 90Y (Rx90Y) entire cohort, (b) MAA versus Rx90Y nonsegmental treatment, (c) MAA versus Rx90Y segmental treatment, (d) Scout90Y versus Rx90Y entire cohort, (e) Scout90Y versus Rx90Y nonsegmental treatment, and (f) Scout90Y versus Rx90Y segmental treatment.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Njei B, Rotman Y, Ditah I, Lim JK. Emerging trends in hepatocellular carcinoma incidence and mortality. Hepatology 2015; 61:191–199. - PMC - PubMed
    1. Gabr A, Riaz A, Johnson GE, et al. Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: confirmatory multicenter analysis in 45 explants. Eur J Nucl Med Mol imaging 2021; 48:580–583. - PubMed
    1. Garin E, Tselikas L, Guiu B, et al. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol 2021; 6:17–29. - PubMed
    1. Hermann AL, Dieudonné A, Ronot M, et al. Relationship of tumor radiation-absorbed dose to survival and response in hepatocellular carcinoma treated with transarterial radioembolization with 90Y in the SARAH study. Radiology 2020; 296:673–684. - PubMed
    1. Villalobos A, Cheng B, Wagstaff W, et al. Tumor-to-normal ratio relationship between planning technetium-99 macroaggregated albumin and posttherapy yttrium-90 Bremsstrahlung SPECT/CT. J Vasc Interv Radiol 2021;32:752–760. - PubMed

Publication types

MeSH terms

Associated data